Paris (France), 17 July 2019 – WeHealth Digital Medicine, Servier Group’s eHealth division, and Lucine, a pioneering French innovative company specializing in digital therapeutics (also known as DTx), have announced their joint development partnership and distribution license. This is the first eHealth partnership between two French companies in the field of digital therapeutics.
The 10-year agreement was signed a few days after the first DTx Europe-DTx France event held in Bordeaux, and combines the expertise of WeHealth Digital Medicine and Lucine to offer patients and health care professionals digital therapies that fall within Servier Group’s therapeutic areas.
“Through our partnership with Lucine, WeHealth Digital Medicine has joined the world of DTx – solutions designed to treat patients directly by administering proven digital therapies, thus bringing new hope to millions of patients,” said Dr David Guez, Director of WeHealth Digital Medicine.
According to the terms of the agreement, WeHealth Digital Medicine will help to cover development costs, including clinical trials, and will pay royalties to Lucine on future sales.
Digital therapeutics, also called DTx, are solutions that offer a therapeutic effect proven through robust clinical trials. They can be used alone or combined with medication in order to improve patients’ health.
“This partnership with WeHealth Digital Medicine, whose human and environmental values are similar to our own, will make it possible to accelerate tomorrow’s medicine. DTx are the most promising innovations in delivering personalized care to patients, especially those with chronic disease. We are talking about action that is both physiological and biological and opens up new possibilities in the range of treatments available to health care professionals,” said Maryne Cotty-Eslous, CEO of Lucine.
Commercialization of the first solutions is scheduled for 2021.
 Therapeutic solution delivered by software to treat/prevent/relieve symptoms and/or disease.
About WeHealth Digital Medicine
Launched in November 2016, WeHealth Digital Medicine, the eHealth division of the Servier Group aims to improve the daily lives of patients and health professionals alike using digital means. WeHealth Digital Medicine proposes innovative digital and connected solutions and services by making the most of collected data, to ensure better individual monitoring of the patient and to better prevent and predict the disease progression. In an open innovative approach, WeHealth Digital Medicine identifies the most promising start-ups in eHealth, in France and internationally, to co-develop solutions. In this way, WeHealth Digital Medicine contributes to the creation of an ecosystem of partners to facilitate and accelerate the development, industrialization, and distribution of innovations and to render them accessible to the greatest number. For further information: https://www.wehealth-digitalmedicine.com/
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22 000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
More information: www.servier.com
Sonia Marques : firstname.lastname@example.org – Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
Jean-Clément Vergeau : email@example.com – Tel. +33 (0)1 55 72 46 16 / + 33 (0) 6 79 56 75 96
Karine Bousseau : firstname.lastname@example.org – Tel. +33 (0)1 55 72 60 37 / + 33 (0) 6 49 92 16 05
Lucine a pioneering French innovative company specializing in digital therapeutics (also known as DTx ),
offers two technologies, LUCINE SCALE and LUCINE CARE and personalized non-medicated care that meets the primary requirements of evidence-based medicine for regulatory and scientific recognition. The chief focus of Lucine, which can conduct preclinical, clinical, and medical-economic validation studies, is patients and their needs. More information: https://lucine.io/